234 related articles for article (PubMed ID: 33971281)
41. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
42. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
[TBL] [Abstract][Full Text] [Related]
43. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW
Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319
[TBL] [Abstract][Full Text] [Related]
44. TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
Turrubiartes-Martínez E; Bodega-Mayor I; Delgado-Wicke P; Molina-Jiménez F; Casique-Aguirre D; González-Andrade M; Rapado I; Camós M; Díaz-de-Heredia C; Barragán E; Ramírez-Orellana M; Aguado B; Figuera Á; Martínez-López J; Fernández-Ruiz E
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33260630
[TBL] [Abstract][Full Text] [Related]
45. A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML.
Chen BR; Deshpande A; Barbosa K; Kleppe M; Lei X; Yeddula N; Vela PS; Campos AR; Wechsler-Reya RJ; Bagchi A; Meshinchi S; Eaves C; Jeremias I; Haferlach T; Frank DA; Ronai Z; Chanda S; Armstrong SA; Adams PD; Levine RL; Deshpande AJ
Blood; 2021 Jun; 137(24):3403-3415. PubMed ID: 33690798
[TBL] [Abstract][Full Text] [Related]
46. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
47. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
[TBL] [Abstract][Full Text] [Related]
48. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease.
Cui X; Teng Y; Hu Y; Li Q; Pei H; Yang Z
Int Immunopharmacol; 2024 Jan; 126():111238. PubMed ID: 37988912
[TBL] [Abstract][Full Text] [Related]
50. Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series.
Hu M; Liu R; Li J; Zhang L; Cao J; Yue M; Zhong D; Tang R
Ann Hematol; 2023 Sep; 102(9):2445-2457. PubMed ID: 37209119
[TBL] [Abstract][Full Text] [Related]
51. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.
Leitner NR; Witalisz-Siepracka A; Strobl B; Müller M
Cytokine; 2017 Jan; 89():209-218. PubMed ID: 26631911
[TBL] [Abstract][Full Text] [Related]
52. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor.
Gakovic M; Ragimbeau J; Francois V; Constantinescu SN; Pellegrini S
J Biol Chem; 2008 Jul; 283(27):18522-9. PubMed ID: 18456658
[TBL] [Abstract][Full Text] [Related]
53. JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.
Benyoucef A; Haigh K; Cuddihy A; Haigh JJ
Leukemia; 2022 Dec; 36(12):2802-2816. PubMed ID: 36229595
[TBL] [Abstract][Full Text] [Related]
54. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease.
Hernandez-Rocha C; Vande Casteele N
Curr Opin Pharmacol; 2020 Dec; 55():99-109. PubMed ID: 33207299
[TBL] [Abstract][Full Text] [Related]
55. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
[TBL] [Abstract][Full Text] [Related]
56. JAK-STAT signaling maintains homeostasis in T cells and macrophages.
Fortelny N; Farlik M; Fife V; Gorki AD; Lassnig C; Maurer B; Meissl K; Dolezal M; Boccuni L; Ravi Sundar Jose Geetha A; Akagha MJ; Karjalainen A; Shoebridge S; Farhat A; Mann U; Jain R; Tikoo S; Zila N; Esser-Skala W; Krausgruber T; Sitnik K; Penz T; Hladik A; Suske T; Zahalka S; Senekowitsch M; Barreca D; Halbritter F; Macho-Maschler S; Weninger W; Neubauer HA; Moriggl R; Knapp S; Sexl V; Strobl B; Decker T; Müller M; Bock C
Nat Immunol; 2024 May; 25(5):847-859. PubMed ID: 38658806
[TBL] [Abstract][Full Text] [Related]
57. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
58. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
60. Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Coffey GP; Feng J; Betz A; Pandey A; Birrell M; Leeds JM; Der K; Kadri S; Lu P; Segal J; Wang YL; Michelson G; Curnutte JT; Conley PB
Clin Cancer Res; 2019 Feb; 25(4):1174-1184. PubMed ID: 30333224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
